First Report of Head and Neck Squamous Cell Carcinoma Treatment Individualised by Geriatric Assessment
Fit and unfit elderly patients derive different benefit from systemic treatment for HNSCC
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1648 results
Lenvatinib Provides Encouraging Responses in Advanced or Metastatic Thymic Carcinoma
Second-line treatment with lenvatinib shows promising anti-tumour activity
Adding Pembrolizumab to Neoadjuvant Chemotherapy Improves Outcome in Early TNBC
Neoadjuvant therapy with pembrolizumab plus chemotherapy provides greater anti-tumour activity than placebo plus chemotherapy in patients with early stage triple negative breast cancer
Significant PFS Benefit Observed with Veliparib plus Carboplatin and Paclitaxel in Patients with Advanced HER2-negative Breast Cancer and BRCA1/2 Mutations
Adding veliparib to carboplatin and paclitaxel doubled the 3-year progression-free survival rate over carboplatin and paclitaxel
Final FLAURA Results Demonstrate Overall Survival Benefit with Osimertinib Over TKIs in Advanced NSCLC
Exploratory analysis of FLAURA data demonstrates that longitudinal ctDNA monitoring can provide early detection of disease progression and/or resistance in advanced NSCLC
LOXO-292 Demonstrates Promising Anti-Tumour Activity in RET-Altered Thyroid Cancer
The results from LIBRETTO-001 trial
Dual HER2 Blockade in Patients With HER2-Amplified Metastatic Colorectal Cancer
TRIUMPH and MOUNTAINEER demonstrate promising clinical benefit for dual HER2 blockade in patients with HER2-amplified metastatic CRC; however, HERACLES-B did not meet the primary endpoint
First-Line Pembrolizumab Versus Chemotherapy in Patients with Advanced G/GEJ Cancer Demonstrates Similar Survival and HRQoL
A subset of patients with MSI-H tumours demonstrated superior benefit from pembrolizumab, both in combination with chemotherapy or as monotherapy
Molecular Classification Is Prognostic of Adjuvant Treatment Benefit in Patients with High-Risk Endometrial Cancer
Differences in patient outcome were observed in four molecular subgroups after adjuvant chemotherapy plus radiotherapy or radiotherapy
Gut Microbiota May Support an Immune Tolerant Profile That Affects Ipilimumab Activity
Gut microbial metabolites may alter the activity of immune blockade agents
Incorporating Veliparib into Chemotherapy and Continuing with Veliparib Maintenance Significantly Improved PFS in Newly Diagnosed High-Grade Serous Ovarian Cancer
The veliparib consisting regimen improved progression-free survival in the overall patient population and among women with BRCA mutation or HRD as compared to chemotherapy
Breakthrough from PAOLA1 GINECO/ENgOT-ov25 trial: Adding Olaparib to Bevacizumab Maintenance Demonstrates Substantial Clinical Benefit in Newly Diagnosed Advanced Ovarian Cancer
Progression-free survival was significantly increased with olaparib plus bevacizumab as maintenance therapy overall and across prespecified subgroups